natgillin/translations-raw huggingface dataset:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A sunflower plant according to any of claims 1-5 comprising the imidazolinone herbicide-resistance characteristics of line GM40 or GM1606, a sample of seed of the line having been respectively deposited with the ATCC Patent Deposit Number PTA-6716 or the ATCC Patent Deposit Number PTA-7606, wherein said plant: 
Biljka suncokreta prema bilo kojem od zahtjeva 1 do 5, naznačena time, da obuhvaća svojstva imidazolinona otpornog na herbicide linije GM40 ili GM1606, uzorak sjemena linije koja je bila deponirana pri ATCC Patent Deposit Number PTA-6716 odnosno pri ATCC Patent Deposit Number PTA-7606, pri čemu je biljka:
R'2 is selected from hydrogen and halo; 
R'2 je odabran od vodika i halo;
The use of a compound according to any one of claims 1 to 2 for the manufacture of a medicament for the treatment or prevention of neoplastic diseases and immune system disorders. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 3, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju neoplastičnih bolesti i poremećaja imunološkog sustava.
A combination comprising a therapeutically effective amount a compound according to any one of claims 1 to 2 and one or more further drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders. 
Kombinacija, naznačena time, da sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 3, te jednu ili više drugih ljekovitih tvari, pri čemu je spomenuta druga ljekovita tvar korisna u liječenju neoplastičnih bolesti i poremećaja imunološkog sustava.
Use of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR, wherein the disease to be treated is selected from proliferative diseases. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti koje odgovaraju na inhibiciju od FAK i/ili ALK i/ili ZAP-70 i/ili JGF-IR, pri čemu se bolest koja se treba liječiti odabire od proliferativnih bolesti.
The use according to claim 8, wherein the proliferative disease to be treated is selected from a tumor of, breast, renal, prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas. 
Uporaba prema zahtjevu 8, naznačena time, da se proliferativna bolest koja se treba liječiti odabire od tumora sljedećih vrsta: dojke, renalni, prostate, kolorektalni, tiroidni, jajnika, gušterače, neuronalni, plućni, materični i gastro-intestinalni tumori kao i osteosarkomi i melanomi.
The use according to claim 6, wherein the disease to be treated is an immune disease. 
Uporaba prema zahtjevu 7, naznačena time, da bolest koja se treba liječiti je imunološka bolest.
The pharmaceutical composition of either claim 1 or 2, wherein the mammal was previously immunized with Bacillus Calmette-Guerin (BCG). 
Farmaceutski pripravak u skladu s bilo patentnim zahtjevom 1 ili 2, naznačen time što je sisavac prethodno imuniziran cjepivom Bacillus Calmette-Guérin (BCG).
The pharmaceutical composition of claim 9, wherein the Mtb72f fusion protein is a polypeptide consisting of residues 1 and 4-725 of SEQ ID NO:4 optionally with a His tag inserted following the initial Met residue. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 i 4-725 iz SEQ ID NO:4, izborno s ubačenim biljegom His iza početnog ostatka Met.
The pharmaceutical composition of any one of claims 1 to 11, wherein the adjuvant is selected from the group consisting of 3D-MPL and QS21 in a liposome formulation and 3D-MPL and QS21 and an oil in water emulsion. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što se adjuvans bira iz skupine koju čine 3D-MPL i QS21 u liposomskoj formulaciji i 3D-MPL, QS21 i emulzija tipa ulje u vodi.
Scooter according to claim 1 or 2, wherein the seat is substantially flat and rectangular and provides a comfortable seat, also in the collapsed position. 
Skuter prema zahtjevu 1 ili 2, gdje je sjedalo (24) u biti plosnato i pravokutno, udobno je, također u uvučenom položaju.
Scooter according to one of the preceding claims, wherein the transmission (6) includes two endless transmission elements, such as belts or chains, which are arranged in series and each connect transmission wheels of different diameters. 
Skuter prema jednom od prethodnih zahtjeva, gdje prijenos (6) obuhvaća dva beskrajna elementa prijenosa, kao što je remen ili lanac, koji se nalaze u seriji i svaki povezuje prijenosna kola različitih promjera.
Scooter according to one of the preceding claims, wherein the rear frame part (2) comprises a hand grip (26) behind the seat (24), an actuating member for actuating a lock of the rotary axis being arranged below the grip. 
Skuter prema jednom od prethodnih zahtjeva, gdje stražnji dio okvira (2) obuhvaća ručku (26) iza sjedala (24), pokretni član koji pokreće zaključavanje osi zakretanja i nalazi se ispod ručke.
The use of a composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium in the manufacture of a medicament, wherein the medicament is formulated for administration to a subject under conditions such that the expression of a complement gene is reduced in the cerebral cortex of said subject for the treatment or prevention of Alzheimer's disease. 
Pripravak koji se koristi u proizvodnji lijeka sadrži suhi, neživi kvasac obogaćen selenom, naznačen time da u ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, pri čemu je lijek formuliran za primjenu u subjektu pod uvjetom da se izražavanje komplement gena smanjuje u moždanoj kori tog subjekta u svrhu liječenja ili prevencije Alzheimerove bolesti.
The use of a composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium in the manufacture of a medicament for inhibiting the expression of a gene involved in processing amyloid precursor protein in a subject at risk of displaying pathology indicative of Alzheimer's disease and a subject having Alzheimer's disease, wherein the medicament is formulated for administration to said subject under conditions such that the expression of a gene involved in processing amyloid precursor protein or a gene involved in the generation of b-amyloid peptide is reduced. 
Pripravak koji se koristi u proizvodnji lijeka sadrži suhi, neživi kvasac obogaćen selenom, naznačen time da u ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, a lijek je namijenjen za inhibiciju izražavanja gena koji sudjeluje u procesiranju amiloidnog proteinskog prekursora u subjektu koji je izložen riziku patoloških simptoma koji su indikativni za Alzheimerovu bolest te u subjektu koji boluju od Alzheimerove bolesti, pri čemu je lijek formuliran za primjenu u subjektu pod uvjetom da se izražavanje gena koji sudjeluje u procesiranju amiloidnog proteinskog prekursora ili gena koji sudjeluje u stvaranju b-amiloidnog peptida smanjuje.
The use of any of the Claims 1 to 8, wherein said composition comprising said dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium is co-formulated with an Alzheimer's therapeutic. 
Primjena bilo kojeg od Zahtjeva 1-8, naznačena time da navedeni pripravak sadrži suhi, neživi kvasac obogaćen selenom, u čijem ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, a koji je formuliran u terapeutiku za liječenje Alzheimerove bolesti.
The use of any of the Claims 1 to 13, wherein said composition comprising said dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium is co-formulated with an antioxidant. 
Primjena bilo kojeg od Zahtjeva 1-13, naznačena time da navedeni pripravak sadrži suhi, neživi kvasac obogaćen selenom, u čijem ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, a koji je zajedno formuliran s antioksidansom.
A composition comprising a dried, nonviable seleniumenriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium, an Alzheimer's therapeutic, and an antioxidant. 
Pripravak naznačen time da sadrži suhi, neživi kvasac obogaćen selenom, u čijem ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, terapeutik za liječenje Alzheimerove bolesti i antioksidans.
A compound represented by the formula 
Spoj prema formuli [image]
A compound according to claim 1, wherein the compound is Nalmefene HCl dihydrate. 
Spoj prema zahtjevu 1, gdje je spoj u kristalnom obliku.
A compound according to claim 2, wherein the compound in a crystalline form is characterized by an X-ray powder diffraction spectrum in 2θ values using Cu Ka1 radiation having a peak at 8.99. 
Spoj prema zahtjevu 2, gdje je spoj u kristalnom obliku naznačen spektrom rendgenskog zračenja praška u 2θ vrijednostima pomoću Cu Ka1 zračenja s maksimumom na 8.99.
A compound according to claim 3, wherein the compound in a crystalline form is further characterized by an X-ray powder diffraction spectrum in 2θ values using Cu Ka1 radiation having a peak at one or more of 10.63, 15.24, 16.55, and/or 17.20. 
Spoj prema zahtjevu 3, gdje je spoj u kristalnom obliku dalje naznačen spektrom rendgenskog zračenja praška u 2θ vrijednostima pomoću Cu Ka1 zračenja s maksimumom na jednom ili više 10.63, 15.24, 16.55 i/ili 17.20.
mixing Nalmefene hydrochloride (17-(cyclopropylmethyl)-4,5-a-epoxy-6-methylenemorphinan-3,14-diol hydrochloride) and aqueous solution such as water, 
miješanje nalmefen hidroklorida (17-(ciklopropilmetil)-4,5-a-epoksi-6-metilenmorfinan-3,14-diol hidroklorida) i vodene otopine kao što je voda,
optionally, heating the mixture, 
po izboru, zagrijavanje smjese,
optionally, distilling the mixture, 
po izboru, destiliranje smjese,
stirring the mixture until transformation is complete, and 
miješanje smjese sve dok transformacija ne bude potpuna, i
heating of the mixture to obtain a substantially homogenous solution, 
zagrijavanje smjese radi dobivanja u biti homogene otopine,
optionally, distillation of the mixture obtained in (b), 
po izboru, destiliranje smjese dobivene u koraku (b),
cooling of the solution obtained in step (b) or (c), subsequently seeding with Nalmefene hydrochloride, and 
hlađenje smjese dobivene u koraku (b) ili (c), zatim dodavanje klice nalmefen hidroklorida, i
The use of any of the Claims 1 to 5, wherein said composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium is co-administered with an antioxidant. 
Primjena bilo kojeg od Zahtjeva 1-13, naznačena time da navedeni pripravak sadrži suhi, neživi kvasac obogaćen selenom, u čijem ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, a koji je zajedno formuliran s antioksidansom.
and R3 are the same or different and each is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; 
i R3 su isti ili različiti i svaki je atom vodika, atom halogena, opcijski supstituirana ugljikovodična skupina ili opcijski supstituirana hidroksi skupina;
The pharmaceutical composition of claim 1, wherein X is a C1-6 alkylene group. 
Spoj prema zahtjevu 1, naznačen time, da X je C1-6alkilen skupina.
The pharmaceutical composition of claim 1, wherein R is a hydroxy group. 
Spoj prema zahtjevu 1, naznačen time, da R je hidroksi skupina.
A pharmaceutical composition according to claim 1, further comprising cyclodextrin. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da sadrži:
A pharmaceutical composition according to claim 1 or 2, wherein said HDAC inhibitor is: 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni arginin.
A pharmaceutical composition according to any one of claims 1 to 5, wherein the molar ratio of meglumine to said HDAC inhibitor is at least 0.5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibitoru najmanje 0,5.
A pharmaceutical composition according to any one of claims 1 to 5, wherein the molar ratio of meglumine to said HDAC inhibitor is 0.5 to 5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibitoru najmanje 0,5 do 5.
A pharmaceutical composition according to any one of claims 1 to 9, which is in the form of a powder, granules, tablets, or a lyophilate/lyophilisate. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 10, naznačen time, da je u obliku praška, granula, tableta ili liofilata/liofilizata.
A pharmaceutical composition according to any one of claims 1 to 36, for use in a method of treatment of a proliferative condition. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 36, naznačen time, da je za uporabu u postupku liječenja proliferativnih stanja.
A pharmaceutical composition according to any one of claims 1 to 36, for use in a method of treatment of cancer. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 36, naznačen time, da je za uporabu u postupku liječenja raka.
A process for obtaining a mixture of trifluoroacetyl glatiramer acetate, wherein during the process a batch of mixture of polypeptides, each of which consists essentially of alanine, γ-benzyl glutamate, tyrosine and trifluoroacetyl lysine is deprotected with a solution of hydrobromic acid in acetate acid, the improvement comprising use of a solution of hydrobromic acid in acetate acid, which solution comprises less than 1000 ppm of metal ion impurities. 
Postupak za dobivanje smjese trifluoracetil glatiramer acetata, naznačen time, da se za vrijeme postupka, šarži smjese polipeptida, od kojih se svaki sastoji od alanina, γ-benzil glutamata, tirozina i trifluoracetil lizina, skida zaštita otopinom bromovodične kiseline u octenoj kiselini, kod čega poboljšanje obuhvaća uporabu otopine bromovodične kiseline u octenoj kiselini, koja otopina sadrži manje od 1000 ppm nečistoća metalnim ionima i manje od 0,5% slobodnog broma.
The process of claim 1-2, wherein the solution of hydrobromic acid in acetate acid comprises less, than 0.1% of free bromide, less than 0.05% of free bromine, less than 0.01% of free bromine, less than 0.001% of free bromine, or is free of free bromine. 
Postupak prema patentnom zahtjevu 1, naznačen time, da otopina bromovodične kiseline u octenoj kiselini sadrži manje od 0,1% slobodnog broma, manje od 0,05% slobodnog broma, manje od 0,01% slobodnog broma, manje od 0,001% slobodnog broma ili je bez broma.
The process of claim 1 or 2, wherein the solution of hydrobromic acid in acetate acid comprises less than 500 ppm of metal ion impurities, less than 100 ppm of metal ion impurities, less than 10 ppm of metal ion impurities, or is free of metal ion impurities. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time, da otopina bromovodične kiseline u octenoj kiselini sadrži manje od 500 ppm nečistoća metalnim ionima, manje od 100 ppm nečistoća metalnim ionima, manje od 10 ppm nečistoća metalnim ionima, ili je bez nečistoća metalnim ionima.
The process of any one of claims 1-4, wherein the solution is 10-36% hydrobromic acid in acetate acid. 
Postupak prema jednom od patentnih zahtjeva 1-3, naznačen time, da je otopina 10-36%-tna bromovodična kiselina u octenoj kiselini.
The process of claim 16, wherein the solution is 33% hydrobromic acid in acetic acid. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je otopina 33%-tna bromovodična kiselina u octenoj kiselini.
The process of any one of claims 1-5, wherein the solution is pretreated with bromine scavenger in order to remove free bromine. 
Postupak prema jednom od patentnih zahtjeva 1-5, naznačen time, da nadalje sadrži stupanj predobrade otopine hvatačem broma, da bi se odstranio slobodni brom.
The process of any one of claims 1-19, wherein the solution is produced in a non-metallic reactor. 
Postupak prema jednom od patentnih zahtjeva 1-7, naznačen time, da se otopina priprema u nemetalnom reaktoru.
The process of any one of claims 1-8, wherein the solution is prepared in a glass-lined or polytetrafluoroethylene-lined reactor. 
Postupak prema jednom od patentnih zahtjeva 1-8, naznačen time, da se otopina priprema u staklom obloženom ili politetrafluoretilenom obloženom reaktoru.
The process of any one of claims 1-10, wherein the color of the hydrobromic acid in acetate acid solution is less than 2000 APHA, less than 1000 APHA, less than 700 APHA, or less than 500 APHA. 
Postupak prema jednom od patentnih zahtjeva 1-9, naznačen time, da je boja bromovodične kiseline u otopini octene kiseline niža od 2000 APHA, niža od 1000 APHA, niža od 700 APHA ili niža od 500 APHA.
A composition comprising the trifluoroacetyl product produced by the process of any of claims 1-25, and a carrier. 
Sastav, naznačen time, da sadrži trifluoracetilni produkt proizveden postupkom prema jednom od patentnih zahtjeva 1-10, te nosilac.
hydrolyzing glatiramer acetate to obtain a hydrolyzate; 
hidroliziranje glatiramer acetata da se dobije hidrolizat;
eluting the hydrolyzate through a chromatographic column; 
eluiranje hidrolizata kroz kromatografsku kolonu;
eluting the sample solutions through the column of step b); and 
eluiranje otopina uzoraka kroz kolonu iz stupnja b); i
A benzazepine compound represented by general formula (1) wherein R1 is a group of (1-3) to (1-6): 
Spoj benzazepina, naznačen time, da je predstavljen općom formulom (1) [image] gdje:
A pharmaceutical preparation comprising the benzazepine compound of claim 1 or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable diluent and/or carrier. 
Farmaceutski pripravak, naznačen time, da sadrži spoj benzazepina iz zahtjeva 1 ili njegovu farmakološki prihvatljivu sol, te farmakološki prihvatljiv razrjeđivač i/ili nosač.
The pharmaceutical preparation according to claim 4 which is used as a vasodilator, hypotensive drug, aquaretic agent, or platelet aggregation inhibitor. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time, da se koristi kao vazodilator, hipotenzijski lijek, akvaretičko sredstvo ili inhibitor agregacije pločastih stanica.
A benzazepine compound represented by general formula (1) wherein R1 is a group of (1-1): 
Spoj benzazepina, naznačen time, da je predstavljen općom formulom (1) [image] gdje:
The composition of claim 5 formulated for pharmaceutical administration and wherein the carrier is a pharmaceutically acceptable carrier. 
Smjesa prema zahtjevu 3 oblikovana za farmaceutsku primjenu i u kojoj je nosač farmaceutski prihvatljivi nosač.
The composition of claim 3 or 4, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Spoj, njegova farmaceutski prihvatljiva sol ili smjesa prema zahtjevu 5, za uporabu u liječenju bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.